NCAM1 and ovarian neoplasm: In order to assess the efficacy of eNKs against metastatic abdominal ovarian tumors, increasing dosages of eNKs, ranging from 0.4 × 107 to 3.2 × 107 CD56+ cells/dose with a total of three doses every other day, were administrated to xenograft NCG mice at one day post-intraperitoneal injection of Skov3-luc OC cells.